| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 96.457 | 166.968 | 145.593 | 122.216 | 226.898 | 629.091 | 1.182.224 | 1.553.463 | 1.130.122 | 1.006.581 |
| Total Income - EUR | 96.476 | 168.403 | 145.942 | 122.386 | 227.516 | 637.064 | 1.202.786 | 1.564.921 | 1.130.153 | 1.006.598 |
| Total Expenses - EUR | 73.251 | 154.593 | 148.359 | 90.358 | 194.956 | 497.435 | 906.997 | 1.454.791 | 970.211 | 960.753 |
| Gross Profit/Loss - EUR | 23.225 | 13.810 | -2.417 | 32.028 | 32.560 | 139.629 | 295.789 | 110.129 | 159.943 | 45.846 |
| Net Profit/Loss - EUR | 19.304 | 10.923 | -4.516 | 30.804 | 30.459 | 134.295 | 281.509 | 96.482 | 137.900 | 38.921 |
| Employees | 1 | 2 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 4 |
Check the financial reports for the company - Daiopharm Consulting Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 19.341 | 10.912 | 10.120 | 11.132 | 21.370 | 15.732 | 33.535 | 77.103 | 59.488 | 44.046 |
| Current Assets | 48.401 | 120.187 | 99.414 | 59.108 | 129.203 | 422.538 | 514.741 | 367.249 | 567.710 | 351.456 |
| Inventories | 3.587 | 5.564 | 22.920 | 32.550 | 71.687 | 118.909 | 203.699 | 97.308 | 100.550 | 88.993 |
| Receivables | 13.922 | 38.469 | 26.717 | 38.586 | 70.335 | 241.638 | 285.730 | 180.006 | 543.357 | 302.035 |
| Cash | 30.891 | 76.155 | 49.777 | -12.028 | -12.820 | 61.991 | 25.312 | 89.935 | -76.197 | -39.572 |
| Shareholders Funds | 18.383 | 29.117 | 19.511 | 49.957 | 79.449 | 212.238 | 351.282 | 235.379 | 182.708 | 80.638 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 49.358 | 101.983 | 90.023 | 20.283 | 71.124 | 226.032 | 196.994 | 208.972 | 444.490 | 314.863 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Daiopharm Consulting Srl